8-K: Aadi Bioscience Reports Q1 2024 Financial Results and Provides Corporate Update

Aadi Bioscience announced its Q1 2024 financial results, including FYARRO sales of $5.4 million, and provided an update on its clinical trial progress.

Summary

• Aadi Bioscience reported first quarter 2024 financial results, with FYARRO net product sales reaching $5.4 million.
• This represents an 8.8% decrease compared to the same period last year, attributed to distributor ordering patterns and fewer new patient initiations.
• The company's PRECISION1 trial is now fully enrolled, with a two-thirds interim analysis expected in Q3 2024 and full results anticipated in early 2025.
• Two Phase 2 trials for EEC and NETs are actively enrolling, with initial data expected later this year.
• Aadi's cash, cash equivalents, and short-term investments totaled $88.3 million as of March 31, 2024, which is expected to fund operations into Q4 2025.
• The net loss for the quarter was $18.3 million, compared to a net loss of $15.2 million for the same period in 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has made progress in clinical trials, the decrease in sales and increased net loss are concerning. The company's cash runway is positive, but the financial performance is mixed.

Positives

• The PRECISION1 trial is now fully enrolled, which is a significant milestone for the company's development program.
• The company has two Phase 2 trials actively enrolling patients, indicating progress in expanding the potential use of nab-sirolimus.
• Aadi has sufficient cash reserves to fund operations into Q4 2025, providing financial stability for ongoing research and development.
• FYARRO is established as the preferred treatment for malignant PEComa after two years on the market.

Negatives

• FYARRO sales decreased by 8.8% compared to the same quarter last year, indicating a potential slowdown in revenue growth.
• The company experienced a net loss of $18.3 million for the quarter, which is an increase compared to the $15.2 million loss in the same period last year.
• The decrease in sales was attributed to distributor ordering patterns and fewer new patient initiations, which may indicate underlying issues in market penetration or demand.

Risks

• The company faces risks associated with the clinical development and regulatory approval of FYARRO in additional indications.
• There are risks associated with the ability to successfully commercialize FYARRO and demonstrate its efficacy in clinical trials.
• Unforeseen adverse reactions or side effects may occur during the commercialization and testing of FYARRO.
• The company's estimates regarding future expenses, capital requirements, and the need for additional financing may be inaccurate.

Future Outlook

The company anticipates providing the two-thirds interim analysis of the PRECISION1 trial in Q3 2024 and full results in early 2025. Initial data from the Phase 2 trials in EEC and NETs are expected later in 2024. The company expects to return to sales growth in Q2. Current cash reserves are expected to fund operations into Q4 2025.

Management Comments

• Dave Lennon, President and CEO, stated that the PRECISION1 trial is now fully enrolled and the company's development plan continues to gain momentum.
• Dave Lennon also mentioned that FYARRO continues to perform well and has cemented its position as the preferred treatment for malignant PEComa.

Industry Context

Aadi Bioscience is operating in the precision oncology space, focusing on therapies for cancers with alterations in the mTOR pathway. The company's focus on nab-sirolimus and its application in various tumor types aligns with the broader industry trend of targeted therapies. The termination of the collaboration with Mirati/Bristol Myers Squibb reflects a strategic shift towards prioritizing internal development programs.

Comparison to Industry Standards

• Aadi's FYARRO sales of $5.4 million in Q1 2024 are relatively modest compared to larger pharmaceutical companies with established oncology products.
• Companies like Exelixis, which focuses on cancer therapies, reported Q1 2024 revenues of $426.2 million, highlighting the scale difference.
• However, Aadi is a smaller, commercial-stage company focused on a niche market (PEComa) and is in the process of expanding its pipeline.
• The company's focus on mTOR pathway inhibition is similar to other companies in the space, such as Novartis, which has also developed mTOR inhibitors.
• Aadi's clinical trial progress with PRECISION1 and Phase 2 trials in EEC and NETs is comparable to other biotech companies in early to mid-stage development.

Stakeholder Impact

• Shareholders may be concerned about the decrease in FYARRO sales and the increased net loss.
• Employees may be impacted by the company's financial performance and strategic shifts.
• Patients may benefit from the continued development of FYARRO and other therapies.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will provide a two-thirds interim analysis of the PRECISION1 trial in Q3 2024.
• The company will release full results of the PRECISION1 trial in early 2025.
• The company will provide initial data from the Phase 2 trials in EEC and NETs later in 2024.
• The company will continue to focus on commercializing FYARRO and expanding its potential indications.

Key Dates

Keywords

Aadi Bioscience, FYARRO, nab-sirolimus, PRECISION1, mTOR, oncology, clinical trials, PEComa, EEC, NETs, financial results